Categories Uncategorized

Grand Rapids One Step Closer to Decriminalizing Entheogenic Plants, Fungi

The city of Grand Rapids, Michigan, may soon deprioritize the enforcement of laws against the use, growing and possession of entheogenic fungi and plants. Grand Rapids city commissioner Kurt Reppart stated that, while this wouldn’t decriminalize the psychedelics, it would allow individuals to gift, grow, use or possess psychedelics without facing any legal charges.

Reppart is in favor of making psychedelics the lowest priority for the city’s law enforcement and believes that the move will not only acknowledge that these fungi and plants can not only be medicines for individuals using them to treat conditions such as anxiety, depression, addiction and PTSD, but that they also save resources.

The move also brings the city one step closer to decriminalization, which is what Decriminalize Nature Grand Rapids, a chapter of the national group that calls for the decriminalization and destigmatization of entheogenic fungi and plants across the country, is working towards. The chapter’s founder and board member Chad Beyer stated that decriminalization was risk reduction given that many people in the city as well as the country were already using these drugs.

The city of Grand Rapids has one of the highest depression rates in the United States. Decriminalize Nature Grand Rapids believes that decriminalization would allow affected individuals who would like to try this alternative to do so.

Some believe that psychedelics are a much better option than current options, given that opioids and antidepressants are not only expensive but also ineffective in some individuals. Opioids are also highly addictive, which makes them dangerous. Beyer, who was diagnosed with an incurable neurological disease known as spinocerebellar ataxia five years ago, revealed that he’d used psilocybin mushrooms as part of his treatment in the past.

The growing interest in psychedelics as well as the destigmatization of mental health also encourages academia to study these substances. The U.S. FDA, the University of California-Berkeley, Johns Hopkins and Yale are some of the many institutions that have conducted studies on entheogenic fungi and plants in a bid to discover their medical benefits.

This isn’t the first city in the state of Michigan to consider psychedelic measures. Last year in September, the city of Ann Arbor decriminalized the cultivation, use and possession of entheogenic plants and fungi. Soon after, Washtenaw County Prosecutor Eli Savit announced that he would not prosecute any cases of cultivation, use or possession of entheogenic plants and fungi, which made these cases a low priority for law enforcement.

The growing wave to decriminalize various psychedelic compounds is coming at a time when a number of companies, including Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), have made progress in developing therapeutic formulations from substances such as psilocybin, or magic, mushrooms and other psychedelics.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

2 months ago